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Between 1955 and the end of 1967, the framework of 
clinical organ transplantation that exists today was 
established in a small number of centers in continental 
Europe, Great Britain, and North America. The kidney 
was, at first, the forerunner organ, but liver transplan-
tation soon became the driving force in discoveries 
and advances that were applicable for other kinds 
'The work was supported by National Institutes of Health (NIH) 
grants DK 29961 and DK 6420. The development of liver transplantation 
was supported continuously over a 40-year period by grants from the 
National Institutes of Health and from the Denver Veterans 
Administration. The chapter was prepared with the indispensable assis-
tance of Ms. Terry L. Mangan (mangantl@msx.upmc.edu). Executive 
Secretary, of the liver transplant program from 1982 to the present. 
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of organs. These accomplishments included the devel-
opment of better methods of organ preservation, the 
evolution of present-day immunosuppression, and the 
elucidation of the seminal mechanisms of alloengraft-
ment and acquired tolerance. In addition, research 
in liver transplantation is responsible for insight into 
the metabolic interrelations of the intra-abdominal 
viscera in disease and health, progress in the under-
standing and treatment of liver-based inborn errors 
of metabolism, and identification of growth factors 
that influence hepatic growth control and regenera-
tion. Table 1-1 summarizes and annotates most of the 
major milestones and events in this complex chain of 
events.I-S8 
Table 1-1. MILESTONES OF LIVER TRANSPLANTATION 
Year 
1955 
1956 
1958-1960 
1960 
1963 
1963 
1963 
1964-1965 
1965 
1966 
1966 
1966-1970 
1967 
1967-1968 
1969 
1973 
19TP~ 1975 
1976 
1979 
1979 
1980 
1981 
1983 
1983-1984 
1984 
1984 
1984 
1987-1989 
1987 
1987 
1988 
Description 
First article in the literature on auxiliary liver transplantation 
First mention of concept of liver replacement 
Formal research programs of total hepatectomy and liver replacement in dogs 
Abdominal multivisceral transplantation described in dogs 
Azathioprine-prednisone cocktail introduced (kidneys first then livers) and recognition of 
organ-induced tolerance 
Description of in situ preservation-procurement method 
First human liver transplantations (University of Colorado) 
Evidence of hepatropic (Iiver-supporHng) factor(s) in portal venous blood 
First clear evidence of hepatic tolerogenicity 
First liver xenotransplantation on July 15, 1966 (chimpanzee donor) 
Clinical introduction of antilymphocyte globulin (ALG) (kidneys,then livers) 
Proof that human leukocyte antigen (HLA) matching would not be a major 
factor in organ transplantation 
First successful human liver replacements: under azathioprine; prednisone, and Aid~ 
Acceptance of brain death concept 
First use of liver transplantation to cure Inborn error of metabolism 
Recognition that the liver resists antibody-mediated rejection 
Principal portal venous hepatotrophlc factor identified as insulin 
Improved slush liver preservation permits long-distance procurement 
Systematic use of arterial and venous grafts for cadaver or~an revascularization . 
Cyclosporine introduced for organ transplantation including two liver recipients 
Cyclosporine-steroid cocktail introduced clinically 
80% 1-year liver recipient survival reported using cyclosporine-prednisone 
Introduction of pump-driven venovenous bypass without anticoagulation 
US consensus development conference conclusion that liver transplantation is 
a service (1983) is followed by rapid proliferation of transplant centers worldwide 
Standardization of in situ preservation-procurement-preservation techniques 
for multiple cadaver organs 
Reversibility demonstrated of B-cell malignancies-post-transplant Iymphoproliferative 
disease (PTLD)-in liver and other organ reCipients 
First reports of reduced-size liver grafts 
First successful transplantation of liver-containing multivisceral grafts 
University of Wisconsin (UW) solution improves liver and other organ preservation 
i<eport of successful extensive use of livers from marginal donors 
Compliance with Organ Transplant Act of 1984 by national adoption of Pittsburgh 
;Joint system for cadaver kidney and liver distribution 
Reference 
2 
3.4 
5 
6 
7 
8 
9,10 
11 
12 
13 
14,15 
16 
17 
18 
19 
20,21 
22,23 
24 
25 
26 
27 
28-30 
31 
32,33 
34 
35,36 
37,38 
39-41 
42 
43,44 
Continued 
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fJablel-l. MILESTONES OF LIVER TRANSPLANTATION-cont'd 
Description Yeor 
1989 
1989 
1989 
1990 
1992-1998 
Popularization of the piggyback variation of liver transplantai'ion 
Clinical introduction of FK506 (tacrolimus)-based immunosuppression 
First report of splitting cadaver livers for 2 recipients 
First successful use of live liver donors (left-side fragments) 
Discovery of donor leukocyte microchimerism in liver (and other organ) recipients with 
recognition of clonal exhaustion-deletion as the seminal mechanism of organ engraftment 
1994-1999 
2001 
Live-donor transplantation of right-side liver fragments 
Development of mechanism-based tolerogenic immunosuppression 
2003 Double knockout of porcine a 1 ,3-galactosyltransferase (G1) gene, revitalizing hopes 
of ciinical xenotransplantation 
Genesis of Liver 
Transplantation 
Transplantation of all the major organs except the liver 
can be traced back to the early 1900s.59•6o In contrast, 
the first report of liver transplantation did not appear 
until 1955 in a journal called Transplantation Bulletin, 
the forerunner of the present day Transplantation. 
The Auxiliary Liver Concept. In a one-page article, 
C. Stuart Welch of Albany Medical College described the 
insertion of a hepatic allograft in the right paravertebral 
gutter of dogs, without disturbing the native liver. 1 
More complete information was published in Surgery 
the following year.61 The auxiliary livers were revascu-
larized by anastomosing the graft hepatic artery to the 
recipient aortoiliac system and by end-to-end anasto-
mosis of the graft portal vein to the host inferior vena 
cava (Fig. 1-1). Welch obviated the need to anastomose 
mUltiple hepatic veins by induding the short length of 
donor retrohepatic vena cava into which all of these 
hepatic veins empty as part of his auxiliary allografts. 
The upper end of the caval segment of the graft was 
anastomosed to the recipient vena cava, and the lower 
end was ligated or sutured (see Fig. 1-1). 
FIGURE 1-1 
Reference 
45 
46,47 
48 
49,50 
51-53 
54-56 
57 
58 
Unlike other kinds of transplanted organs, the auxil-
iary allografts underwent dramatic shrinkage. The atro-
phy, which began within 3 or 4 days, was attributed at 
the time to liver rejection. The view was consistent 
with the current dogma of the time, that liver size and 
regeneration are governed by the volume of portal 
venous inflow (the "flow hypothesis" of hepatic home-
ostasis). Because the portal vein of the transplanted 
extra livers had been provided with an ample amount of 
systemic (i. e., vena caval) blood (see Fig. 1-1), the acute 
allograft atrophy was ascribed to immunological factors. 
A decade passed before it was demonstrated that the 
liver shrinkage actually was due to the dearth in vena 
caval and other systemic blood of molecules (especially 
Auxiliary liver homotransplantation in dogs (the Welch procedure). 
Note that the reconstituted portal venous inflow is from the inferior 
vena caval bed rather than from the splanchnic organs. Biliary drainage 
was with cholecystoduodenostomy. (From Starzl TE, Marchioro TL, 
Rowlands DT Jr, et al: Immunosuppression aiter experimental 
and clinical homotransplantation of the liver. Ann Surg 160:411-439, 
1964.) 
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insulin) that are normally presented to liver in high 
concentrations in splanchnic venous blood (see 
Reassessment of the Auxiliary Liver Graft) .9.10.20.21 
Orthotopic Liver Transplantation. The concept of 
liver replacement (orthotopic transplantation) was first 
mentioned by Jack Cannon in a one-page account of the 
transplant activities in the surgery department of the 
recently founded University of California, Los Angeles 
(UCLA) School of Medicine. 2 The species studied was not 
mentioned (presumably dog), and there was no specific 
information about the procedure. It is noteworthy that 
Cannon's article (entitled "Brief Report") and the two 
articles on auxiliary hepatic transplantation by Welch 
and colleagues1.61 were the sale references to the liver in 
M.F.A. Woodruff's compendium of work in the trans-
plantation field up to 1959.62 
By the time Woodruff's book was published in 1960, 
extensive investigations of liver replacement in dogs 
had been completed in independent studies started 
in the summer of 1958 at both Northwestern University 
in Chicag03 and the Peter Bent Brigham Hospital in 
Boston.4 The Boston studies,4,63,64 under the direction 
of Francis D. Moore, were a natural extension of an 
immunologically oriented institutional commitment to 
organ transplantation that initially was preoccupied 
with the kidney. In contrast, the Northwestern initia-
tive3,65 stemmed from an earlier investigation at the 
University of Miami of the metabolic interrelationships 
of the liver with the pancreas and intestine. 66 .67 
To facilitate these studies, a new method of total hepatec-
tomy was developed in which the unique feature was 
preservation of the host retrohepatic inferior vena cava.68 
The canine host hepatectomy developed in Miami was 
essentially the same as that in today's piggyback varia-
tion of liver transplantation.45,69,70 For liver transplantation 
in the dog, however, it was simpler to excise the host 
retrohepatic vena cava along with the native liver and to 
replace it with the comparable caval segment of the 
donor liver into which the hepatic veins empty. After 
completing the vena caval anastomoses above and below 
the liver, hepatic arterial and biliary tract anastomoses 
were performed with conventional methods (Fig. 1-2).3.4 
When different means of portal revascularization were 
systematically tested in the Northwestern laboratory 
(Fig. 1-3), any deviation from normal of the portal sup-
ply resulted in reduced survival. 
The research teams at Northwestern and Brigham 
Hospital were unaware of each other's activities until 
late 1959, and direct contact was not established until 
the 1960 meeting of the American Surgical Association. 
By then, the cumulative total of liver replacements in 
unmodified (nonimmunosuppressed) dogs had increased 
to 80 in Chicag03 and 31 in Boston.4 The results were 
published separately in 1960 in different journals. 
I-"I~ .... ~ _____ Upper vena cava . 
~ anastomosis 
Repaired portacaval 
shunt 
'i:,lc;ijRE' lD;Di~ 
Completed liver replacement in the dog. The 
fact that the recipient was a dog rather than 
a human is identifiable only by the multilobar 
appearance of the liver. (From Brettschneider L, 
Daloze PM. Huguet C, et al: The use of com-
bined preservation techniques for extended 
storage of orthotopic liver homo grafts. Surg 
Gynecol Obstet 126:263-274, 1968.) 
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~ Liver 
A B c 
FiGlJRE1"'a 
Alternative methods of portal vein revascularization: A, reverse Eck fistula; B, with small side-to-side porta-
caval shunt; C, anatomically normal. Survival was best with C. (From Starz! IE, Kaupp HA Jr, Brock DR, et a1: 
Reconstructive problems in canine liver homotransplantation with special reference to the postoperative role 
of hepatic venous flow. Surg Gynecol Obstet 111:733-743, 1960.) rvc, inferior vena cava; PV, portal vein. 
Prerequisites for Canine 
Liver Replacement 
The two prerequisites for perioperative survival of the 
canine recipients had been identified in both laborato-
ries. The first requirement was prevention of ischemic 
injury to the allograft. This was accomplished in Boston 
by immersing the liver in iced saline. At Northwestern, 
the livers were cooled by the intravascular infusion of 
chilled lactated Ringer's solution (Fig. 1-4). This now uni-
versal first step in preservation of all organs had never 
been used before, apparently because of fear of damaging 
the microcirculation. Better liver preservation was later 
obtained with infusates of differing osmotic, oncotic, and 
electrolyte composition (e.g., the Collins,22 Schalm,23 and 
University of Wisconsin [UWj solutions).39-41 
The second prerequisite for successful canine liver 
transplantation was avoidance of damage to the recipi-
ent splanchnic and systemic venous beds, the drainage 
of which was obstructed during host hepatectomy and 
graft implantation. This was accomplished in both lab-
oratories by decompressing external venovenous 
bypasses, which differed in detail. 
Pathology of Liver Rejection 
Until 1960, the kidney had been the only organ allograft 
Whose unmodified rejection had been systematically 
studied. Most of the transplanted canine livers were 
destroyed in 5 to 10 days. 'TYPically, a heavy concentration 
of mononuclear cells was seen in the portal triads and 
within and around the central veins. Hepatocyte necrosis 
was extensive.64,65 A curious exception was noted, how-
ever, in the 63rd liver replacement experiment. 
In the exceptional recipient, the serum bilirubin 
reached a peak at 11 days, but then progressively 
declined (Fig. 1-5, dashed line}.65 The predominant 
histopathological findings in the allograft by day 21 were 
more those of repair and regeneration than of rejection. 
This was the first recorded exception to the existing 
dogma (based on skin graft research) that rejection, 
once begun, was inexorable. Five years later, similar 
observations were made in allografts of long-surviving 
canine liver recipients in Denver, whose rejections had 
developed and then spontaneously reversed under stable 
daily doses of azathioprine. 11 
Variant Liver Transplant 
Procedures 
The studies completed by the end of 1959 in Boston 
and Chicago defined almost to the last detail the liver 
replacement operation soon to be performed in 
humans. The operation of multivisceral transplanta-
tion, in which the allograft consisted of the liver and all 
of the other intraperitoneal organs, also was perfected 
(Fig. 1-6, center). 5 It was noted that rejection of the dif-
ferent splanchnic organs transplanted with the liver was 
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Cooling of the canine hepatic allograft by infusion of chilled 
lactated Ringer's solution into the donor portal vein. The animals 
were simultaneously exsanguinated. (From Starz! TE, Kaupp HA Jr, 
Brock DR, et al: Reconstructive problems in canine liver homotrans-
plantation with special reference to the postoperative role of hepatic 
venous flow. Surg Gynecol Obstet 1ll:733-743, 1960.) 
much less severe than the rejection of the individual 
organs transplanted alone,71 an observation that was 
validated much later in rodent studies72 ,73 and in 
humans. 74 In addition, the recipients had histopatho-
logical evidence of a widespread graft-versus-host reac-
tion in their tissues, but without overt graft-versus-host 
disease (GVHD). This was the first clue that GVHD 
might not blight intestinal or liver transplantation, 
or both, if such procedures were ever to become 
feasible. 
Multivisceral transplantation and its modifications 
(see Fig. 1-6) were applied in humans 30 years 
later37,38,7s,76 and are now part of the conventional 
armamentarium of advanced organ transplant centers. 
However, when the canine operation was first pre-
sented at the Surgical Forum of the American College 
of Surgeons in October 1960,S it was ridiculed. In fact, 
all research in whole-organ transplantation (including 
of the kidney) during 1958 to 1960 was considered 
naive or wasteful by many critics and especially by basic 
6 
5 
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3 
2 
Control 3 6 9 12 15 18 21 
Days after liver transplant 
FIGURE 1-5 
Serial blood glucose and serum bilirubin levels in a nonimmuno-
suppressed canine liver recipient who survived for 3 weeks. 
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Note the decline of bilirubin after the eleventh day. This evidence 
of the spontaneous reversal of rejection was consistent with the 
histopathology of the autopsy liver at 21 days. (From Starzl TE, 
Kaupp HA Jr, Brock DR, Unman JW: Studies on the rejection of 
the transplanted homologous dog liver. Surg Gynecol Obstet 112: 
135-144, 1961.) 
immunologists, most of whom viewed the immune 
barrier to transplantation as impenetrable. 
Immunosuppression by 
Host Cytoablation 
Just as this kind of surgical research in unmodified 
dogs was losing momentum, it was dramatically 
revitalized by six successful human kidney transplan-
tations performed between January 1959 and February 
1962, first by Joseph Murray in Boston77 and then 
five more times by the independent teams of Jean 
Hamburger78 and Rene KUSS 79 in Paris. The first cases 
were compiled under circumstances that would not be 
acceptable in today's climate of institutional review 
board (IRB) regulation (Le., before long-term survival 
had been accomplished in animals). All six patients were 
preconditioned with sublethal doses of 4.5 Gy total-body 
irradiation (Table 1-2, above the dashed line). Although 
success was defined as survival for at least 1 year, the 
first two recipients (both of fraternal twin kidneys) had 
continuous graft function for more than 2 decades with-
out the need for posttransplant immunosuppression. 
These were the first examples of acquired immuno-
logical tolerance in humans. However, the drug-free state 
was not considered to be real tolerance for reasons 
described in Chapter 73, "Cell Migration, Chimerism, and 
Graft Acceptance, with Particular Reference to the Liver." 
In an effort to replace irradiation for conditioning, 
the UCLA urologist Willard Goodwin pretreated six 
R 
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IKcf~~~;f:KS 
The original canine multivisceral allograft (bottom center) and its variations (anvws). All are used clinically 
today. (From Starzl TE: The saga of liver replacement, with particular reference to the reciprocal influence of 
liver and kidney transplantation (1955-1967), JAm Coll Surg 195:587-610, 2002.) 
human kidney recipients in 1960 to 1961 with myelotoxic 
doses of cyclophosphamide and methotrexate. 8o 
One patient had prolonged survival (143 days), during 
which rejection was successfully reversed several times 
with prednisone. This important observation was not 
reported until 1963. In any event, it quickly became 
apparent that cytoablation would not be the means by 
which liver transplantation could be accomplished. 
Table 1-2. KIDNEY TRANSPLANTATION: 6 MONTHS 
OR GREATER SUR'1IVALASOFMARCH 1963 
City (Ref)* Date Donor Survival (mo) 
Boston (77) 1/24/59 Fraternal twin >50 
2 Paris (78) 6/29/59 Fraternal twin >45 
3 Paris (79) 6/22/60 Unrelated 18 (Died) 
4 Paris (78) 12/19/60 Mother >12 (Died) 
5 Paris (79) 3/12/61 Unrelated 18 (Died) 
6 Paris (78) 2/12/62 Cousin >13 
7 Boston (93) 4/5/62 Unrelated 11 I 
*Boston: Joseph E Murray (patients 1 and 7); Paris: Jean 
Hamburger (patients 2, 4, and 6), R Kuss (patients 3 ana 5), 
In our hands, total-body irradiation precluded even peri-
operative, much less extended, survival of canine liver 
recipients.81 
Drug Immunosuppression 
for Clinical Kidney 
Transplantation 
Since the early 1950s, skin graft survival in rabbits was 
slightly prolonged by treatment with adrenal cortical 
steroids.82,83 However, the era of drug immunosuppres-
sion usually is designated to begin on the arrival of the 
drug 6-mercaptopurine (6-MP). After establishing that 
6-MP was immunosuppressive without a need for overt 
bone marrow depression,84 Schwartz and Dameshek at 
Tufts Medical School in Boston85 and Meeker and Good 
and colleagues at the University of Minnesota86 
demonstrated modest prolongation of skin allograft 
survival in rabbits. Survival of canine kidney allografts 
for up to 40 days under 6-MP was then reported by 
Caine in London87 and independently for similar times 
by Zukoski in Richmond. s8 By the end of 1960, CaIne 
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(by now in Boston with Murray)89,90 and Zukoski (with 
David Hume in Richmond) 91 obtained even longer 
survival of canine kidney recipients, In CaIne's report, 
the best results were obtained with the imidazole 
derivative of 6-MP, azathioprine (Imuran) ,89 However, 
survival for as long as 100 days was unusual (i.e., 
< 5 % of the experiments). 
When clinical kidney transplant trials with the new 
drugs were begun in Boston in 1960 to 1961 with initially 
high expectations,92 the possibility of transplanting the 
human liver no longer seemed so remote. In 1961, 
William R. Waddell left Massachusetts General Hospital 
to become Chair of Surgery at the University of Colorado, 
where one of us (T.E.S) joined him from Northwestern. 
Armed with more than 3 years of experience in Chicago 
with canine hepatic replacement, we settled on liver 
transplantation as our highest priority for clinical devel-
opment. The plan was tabled when we learned that the 
Boston clinical trial of kidney transplantation had yielded 
disappointing results. A ray of hope could be found, 
however, in a report by the future Nobel laureate, Joseph 
Murray, in the September 1962 issue of Annals of 
Surgery.92 
The article included a description of a kidney allograft 
that was still functioning under azathioprine immuno-
suppression 120 days after its transplantation from an 
unrelated donor on April 6, 1962. The kidney was still 
functioning at 10 months when next reported in June 
1963.93 Although the patient's blood urea nitrogen (BUN) 
was now elevated (110 mg/dL), the graft was destined 
to support dialysis-free life for another 7 months (total of 
17 months). It was the first example of I-year survival of 
a human organ allograft without host conditioning with 
total-body irradiation (see Table 1-2, number 7). 
However, this was the only kidney recipient of the first 
13 treated solely with chemical immunosuppression 
who survived for as long as 6 months.n·94 
In the meantime, we had obtained our own supply of 
azathioprine in the spring of 1962 and began systemat-
ically evaluating it at the Denver VA Hospital laboratory 
with the simpler canine kidney model instead of liver 
transplantation. As in other laboratories, our yield of 
survivals of as long as 100 days was small. However, 
two crucial findings were clinically relevant. The first 
was that the kidney rejections that developed with aza-
thioprine invariably could be reversed by the delayed 
addition of large doses of prednisone.95 
The second key observation was that a mean sur-
vival of 36 days in dogs treated with azathioprine was 
almost doubled when the animals also were pretreated 
with the drug for 7 to 30 days.96 We now committed to 
clinical trials of kidney and liver transplantation, in that 
order. Daily doses of azathioprine were given to the 
kidney recipients ior 1 to 2 weeks before, as well as after, 
kidney :ransplantation from living donors, adding 
prednisone only to treat rejection. The human renal trans-
plantation program was opened in the autumn of 1962. 
The two features of the adaptive immune response to 
allografts that would make transplantation of all kinds 
of organs feasible were described in the title of the report 
of the first 10 kidney cases: "The Reversal of Rejection in 
Human Renal Homografts with Subsequent Development 
of Homograft Tolerance."6 The term tolerance referred 
to the time-related decline of need for maintenance 
immunosuppression. Largely because of this observation, 
we already had concluded that renal transplantation had 
reached the level of a bona fide, albeit still flawed, clini-
cal service. At the time, there were only three clinically 
active kidney transplant centers in the United States: 
the long-standing Brigham program and the two cen-
ters opened in 1962-ours at the University of Colorado 
and David Hume's in Richmond, Virginia. 
One year later, nearly 50 kidney teams had started or 
were gearing up, including the program at UCLA that had 
opened in 1960 and closed in 1961. A similar prolifera-
tion of kidney centers also was under way throughout 
Europe. Moreover, the benefits of kidney transplanta-
tion proved to be truly long-lasting in some cases. Eight 
of the Colorado kidney recipients of the 1962 to 1963 
era still bear their original transplants 40 years later 
and are the longest surviving organ allograft recipients 
in the world. 97 
Human Liver Trials of 1963 
Although the follow-ups were still short, our encouraging 
kidney experience triggered the decision to go forward 
with the infinitely more difficult initiative of liver trans-
plantation. The first attempt on March 1, 1963 was in 
an unconscious and ventilator-bound child with biliary 
atresia who bled to death during operation. The next two 
recipients, both adults, died 22 and 7.5 days after their 
transplantations on May 5 and June 3, 1963 for the 
indication of primary liver malignancies (Table 1-3). 
These two patients were found at autopsy to have 
extrahepatic micrometastases.8 
As in the kidney recipients, azathioprine was admin-
istered before as well as after transplantation, adding a 
high-dose course of prednisone with the onset of rejec-
tions. The rejections were easily reversed (Fig. 1-7), 
and the transplanted livers retrieved at autopsy after 
7.5 and 22 days were remarkably free of rejection. Good 
allograft preservation was accomplished by trans femoral 
infusion of a chilled perfusate into the aorta of the nOD-
heart-beating donors after cross-clamping the aorta at 
the diaphragm (Fig. 1-8), in much the same way as in 
the first stage of the flexible multiple organ procurement 
operation used today.32.33 There was little ischemic 
damage to the allografts during the cold ischemia of 
rr 
"Table 1...,3. THE FIRST SEVEN HUMAN LIVER RECIPIENTS 
Age Date City (Ref) liver Disease 
3 311 /63 Denver (8) Biliary atresia 
48 5/5/63 Denver (8) Hepatoma. cirrhosis 
68 6/3/63 Denver (8) Duct cell carcinoma 
52 7/10/63 Denver (9) Hepatoma. cirrhosis 
58 9/16/63 Boston (98) Colon metastases 
29 10/4/63 Denver (9) Hepatoma 
75 1/?/64 Paris (99) Colon metastases 
2.5 and 8 hours, as judged by modest increases in the 
liver injury tests. 
The various anastomoses were performed in the 
same way as in the dog experiments except for the bil-
iary tract reconstruction. The complete operation was 
drawn in 1963 (Fig. 1-9). The picture could be used 
today, and often is, to depict a perfectly executed 
human liver transplantation. The flaw in the trial was 
the use of passive venovenous bypasses. Blood clots 
formed in the bypass tubing, migrated to the lungs, and 
caused or contributed to the deaths of all four of the 
1963 Denver recipients who survived the operation 
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FIGURE 1-7 
Rise in serum bilirubin to 12.8 mg/dL in the first patient who 
survived liver replacement. The bilirubin d~clined after institution 
of high-dose prednisone therapy. The patient died of pulmonary 
emboli after 22 days. (From Starzl TE. Marchioro TL, Von Kaulla KN, 
et al: Homotransplantation of the Ever in humans. Surg Gynecol 
Obstet 117:659-676, 1963.) 
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Survival (Days) Main Cause of Death 
0 Intraoperative bleeding 
22 Pulmonary emboii, sepsis 
75 Pulmonary emboli 
65 Gastrointestinal bleeding. pulmonary 
emboli/edema. liver failure 
11 Pneumonitis. hepatic abscesses. failure 
23 Sepsis. bile peritonitis. pulmonary emboli 
0 Intraoperative hemorrhage 
(see Table 1-3). Overzealous correction of clotting 
abnormalities probably contributed to the formation of 
the emboli. Coagulation had been monitored with 
serial thromboelastograms and corrected with blood 
components and with E-aminocaproic acid (an analogue 
of the currently used aprotinine). 
Ironically, the venous decompression that had been 
critical for survival in the dog experiments is not manda-
tory in most human liver recipients. The motor-driven 
venovenous bypass system, which was introduced in 
Pittsburgh in the 19805,28-30 made the procedure easier; 
but in many centers, it now is used only selectively and 
FI$UREi:S;; 
ExtracorporeaJ perfusion of the deceased donors reported in 1963. 
"The venous drainage was from the inferior vena cava and the 
arterial inflow was through the aorta after insertion of the 
catheters through the femoral vessels. Note clamp on thoracic 
aorta to perfuse the lower half of the corpse selectively. A glucose-
primed pump oxygenator was used with a heat exchanger."8 
I-General Considerations 
FIGURE 1"-9 
The operation carried out in the first two patients who survived 
liver replacement on May 5 and June 3, 1963. The patients lived for 
22 and 7.5 days. (From Starzl TE: Experience in Hepatic 
Transplantation. Philadelphia, Saunders, 1969, p 138.) 
almost never in infants or small children. In fact, venous 
decompression was later shown to be expendable in 
dogs that were submitted to common bile duct ligation 
several weeks in advance of transplantation. With the 
development of venous collaterals in these animals, it 
was possible at a second stage to carry out liver 
replacement without venovenous bypass. IDO 
Liver Transplant Moratorium 
During the last half of 1963, two more liver transplan-
tations were performed in Denver,9 and one each in 
Boston98 and Paris99 (see Table 1-3). After the deaths of 
these patients, clinical activity ceased for 3.5 years, 
between January 1964 and the summer of 1967. The 
worldwide moratorium was voluntary, but the decision 
to stop was reinforced by widespread criticism of 
attempting to replace an unpaired vital organ with an 
operation that had come to be perceived as too formi-
dable to be practical. During the moratorium, advances 
were made, most of which were applicable to all organs. 
Role of Human Leukocyte Antigen 
(HLA) Matching 
In a clinical collaboration with Paul Terasaki of UCLA, 
it was shown that the quality of human leukocyte antigen 
(HLA) matching, short of perfect compatibility, had little 
association with kidney transplant outcome. 14,[S,101 By 
inference, desperately ill liver, heart, and other trans-
plant candidates who could not wait for a well-matched 
organ would not suffer a significant penalty by receiving 
a mismatched one. 
Development of Antilymphocyte 
Globulin (ALG) 
A second objective was to improve immunosuppression, 
Between 1963 and 1966, antilymphocyte globulin (ALG) 
was prepared from antilymphocyte serum (ALS) 
obtained from horses immunized against dog or human 
lymphoid cells.102 After extensive preclinical studies, 
human-specific ALG was introduced clinically in 1966 
in combination with azathioprine and prednisone (the 
triple drug cocktail) .13,16 In the preclinical canine studies, 
the efficacy of dog-specific ALG had been demonstrated 
when it was given before, at the time of, or after kidney 
and liver transplantation. Because pretreatment appeared 
to be valuable, it was incorporated for the patients when-
ever possible. 
Demonstration of Hepatic 
Tolerogenicity 
The feasibility of liver transplantation reflected during 
this period was increasingly evidenced by a growing 
kennel population of long-surviving canine recipients 
(Fig, 1-10), none of which was treated with more 
than a 4-month course of azathioprine il or a few doses 
of ALG.13 In presenting the results of 143 canine liver 
replacements to the Society of University Surgeons in 
February 1965, it was emphasized that "Although the 
early recovery after liver homotransplantations 
has many hazards ... the frequency and rapidity with 
which dogs could be withdrawn from immunosup-
pression without an ensuing fatal rejection is remark-
able,. .. The consistency of this state of host-graft 
nonreactivity and the rapidity with which it seemed 
to develop exceeds that reported after canine renal 
homotransplantations. "il 
A year later, the French surgeon, Henri Garnier, 
reported (with Cordier) that a significant percentage of 
untreated outbred pig liver recipients did not reject 
their allografts. 103 This observation promptly was 
confirmed and extended in England by CaIne at 
Cambridge,104 Peacock and Terblanche in Bristol, lOS and 
US. 106 Caine and colleagues subsequently demonstrated 
that the tolerance self-induced by the liver extended to 
other tissues and organs from the liver donor, but not 
from third-party pigs, 107 
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FIGURE 1-10 
Canine recipient of an orthotopic liver homograft,S years later. The operation was on March 23, 1964. 
The dog was treated for only 120 days with azathioprine and died of old age 13 years after transplantation. 
Reassessment of the Auxiliary Liver Graft 
Although the primary focus during the moratorium was 
on liver replacement, the ostensibly less radical auxiliary 
liver transplantation (Welch's operation) was reevalu-
ated. After showing that rejection could be completely 
prevented in some dogs with high doses of azathioprine, 
it was proved that the acute atrophy of Welch's auxiliary 
livers was caused by depriving the allografts of liver-
supporting constituents of splanchnic venous blood 
(see Fig. 1-1).9.10 The technical difficulties of obtaining 
optimal portal vein revascularization finalized the deci-
sion to proceed clinically with liver replacement. 
However, the hepatotropic qualities of splanchnic 
venous blood were not fully explained until the mid-
1970s. Eventually, it was established that endogenous 
insulin was the most important factor. 20 .21 This was a 
decisive step in understanding the pathophysiology of 
Eck's fistula (portacaval shunt) .108 Only then could it be 
readily understood why total splanchnic venous diver-
sion (i.e., portacaval shunting) was such a severe insult 
to the already damaged liver of patients with hepatic 
disease, particularly if there had been significant portal 
flow prior to the shunt. In addition, the demonstration 
that insulin is a liver growth factor was the beginning of 
the field of hepatotropic physiology (i.e., studies of the 
effect of growth factors on liver structure, size, function, 
and the capacity for regeneration). J09 
Improved Organ Preservation 
The potential pitfall of organ preservation remained. 
It would still be necessary to obtain livers from non-
heart-beating donors. To help surmount this difficulty, we 
developed an ex vivo perfusion system in 1966 and 1967 
that permitted reliable preservation of canine livers for as 
long as a day,uo Now, it was time to try again. 
Resumption of Human Liver 
Replacement 
The liver program was reopened in July 1967 and was 
reinforced by a powerful new member, Carl Gustav Groth, 
a 2-year National Institutes of Health (NIH) fellow 
I 
i 
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FIGURE 1-11 
The first three human recipients to have prolonged survival after 
liver replacements in July and August, 1967. The adult, Carl Groth, 
was then an NIH-supported fellow. 
from Stockholm. Multiple examples of prolonged human 
liver recipient survival promptly were produced under 
triple-drug immunosuppression with azathioprine, pred-
nisone, and ALG (Fig. 1-11).16 
The liver transplant beachhead was reinforced by 
the opening of Roy CaIne's clinical program in 
Cambridge, England in February 1968.69 By the time 
the first textbook on liver transplantation was written 
in 1969,lll there had been 33 human liver replacements 
in the world: 25 in Denver and 8 elsewhere (4 by CaIne). 
The German and French teams of Rudolf Pichlmayr and 
Henri Bismuth began to make important contributions 
to liver transplantation in the early 1970s, followed by 
the Dutch group of Rudi Krom later in the decade. 
Transplantation of other extrarenal organs followed 
close behind the liver, using similar immunosuppres-
sion (Table 1-4). Hearts were successfully transplanted 
in 1968 in Capetown by Barnard 112 and in Palo Alto by 
Shumway.1l3 In 1969, the first prolonged survival after 
human lung1l4 and pancreas transplantation115 was accom-
plished in Ghent, Belgium and Minneapolis, respectively. 
Despite these achievements, transplantation of the 
extrarenal organs, and especially of the liver, remained 
controversial for another decade, because of the high 
mortality rate. Only 34 (20%) of the 170 liver recipients 
treated at the University of Colorado through 1979 sur-
vived for 5 years or longer. 52 
The unusual tolerogenicity of the hepatic allograft 
previously demonstrated in dogs and pigs was evident in 
human liver recipients of the 1970s. In 1995, 12 (28 %) 
of the 42 Colorado patients still surviving from this era 
already had been off all immunosuppression for 1 to 
17 years.1l6 Since then, the majority of the remaining 30, 
some of whom are now beyond the third of a century 
posttransplant milestone, also have stopped drugs with-
out rejection.1l7,llB Such drug-free tolerance was almost 
unheard of with the other kinds of deceased-donor 
organs. 
Advent of Better Drugs 
Although the feasibility of transplanting the liver and 
other extrarenal organs had been established, the wide-
spread use of these procedures was precluded until 
cyclosporine was introduced clinically in England in 
1978 by Calne25 and combined with prednisone in 
Denver 1 year later. 26 Results further improved with all 
Table 1-4. FIRST SUCCESSFUL TRANSPLANTATION OF HUMAN ALLOGRAFTS (SURVIVAL >6 MONTHS) 
Organ City Date Physician/Surgeon Ref 
Kidney t3oston 1/24/59 Murray 77 
Liver Denver 7/23/67 Storzi 16 
Heort Cape Town 1/2/68 Barnard/Shumway 112,113 
Lung' Ghent i 1/14/68 Derom 114 
Pancreas' MinneapOlis 6/3/69 Lillehei 115 
-PaTient aied after 10 months; all others in table lived more than 1 year with functioning graft. The first more than i-year survival 
of isolated lung reCipients was not reportea until 1987. 
'Kidne'( ana oancreas allografts in uremic patient 
organs when tacrolimus was substituted for cyclosporine 
in the 1990s.46,47 The stepwise increases in liver recipient 
survival, first with cyclosporine-based27,1l9 and then with 
tacrolimus-based immunosuppression,46,47 were partic-
ularly striking (Fig. 1-12). Thus, by the end of the 
20th century, transplantation of the liver and all of the 
other vital organs had become an integral part of 
sophisticated medical practice in every developed 
country in the world. The dramatic spread of liver 
transplantation that began in the mid-1980s was made 
possible by a supremely talented new generation of 
surgeons who in turn began to instruct their own com-
petent trainees. 
There was, however, one disappointment. With the 
better immunosuppressants, drug-free liver recipients 
such as those treated with azathioprine (or cyclophos-
phamide), prednisone, and ALG in the mortality-plagued 
1970s were expected to become common. Yet, this was 
seen less frequently than before. It was clear that 
the goal of deliberate production of drug-free liver 
recipients would remain out of reach until the mecha-
nisms leading to organ-induced tolerance were under-
stood. Insight into these mechanisms of tolerance 
began to emerge in 1992 when low-level donor leuko-
cyte chimerism (micro chimerism) was demonstrated 
in all 30 kidney and liver recipients studied from 3 to 
100 
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30 years after successful, transplantation. Chapter 73 
describes how this new information permitted the 
development of more tolerogenic strategies of immuno-
suppression applicable to transplantation of all organ 
allografts. 
Technical Innovations 
Although the ascension of liver transplantation was 
dominated by improvements in immunosuppression, 
there were other significant developments, including 
modifications in the details of both the donor and 
recipient operations. 
Donor Procedures 
Cooling of deceased-donor organs is done today by 
variations of the in situ technique originally developed 
before the acceptance of brain death conditions (see 
Fig. 1-8), but with simple infusion without a bypass. 7 
These methods32,33 allow removal of all thoracic and 
abdominal organs, including the liver, without jeopard-
izing any of the individual organs-even with unstable 
donors, including those whose hearts have ceased 
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Stepwise improvements in patient survival after liver replacement. These were associated with the advent of 
increasingly potent immunosuppressive drugs. A2A, azathioprine; eVA, cyclosporine before [dashed line] 
and after [continuous line] the availability of UW solution; FK, tacrolimus. Most of the difference between 
the dashed and continuous lines was because of the availability of FK for the rescue of cyclosporine failures. 
The data shown here were presented to the American Surgical Association in April 1994. 
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Portal v. (r) 
c~~obDcf-lj: 
Transplantation of a liver piggybacked onto an inferior vena cava, which is preserved through its length. 
Note that the suprahepatic vena cava of the homograft is anastomosed to the antelior wall of the recipient 
vena cava. The retrohepatic vena cava of the homograft is sutured or ligated, leaving a blind sac into which 
empty numerous hepatic veins. (From Tzakis A, Todo S, Starzl TE: Orthotopic liver transplantation with 
preservation of the inferior vena cava. Ann Surg 210:649-652, 1989.) Ao, aorta; rvc, inferior vena cava. 
to beat. By 1987, multiple organ procurement tech-
niques had become so standardized that they were 
interchangeable not only from city to city but also 
from country to country. After the chilled organs are 
removed, subsequent preservation usually is performed 
by simple refrigeration rather than by sophisticated 
methods of continuous perfusion that were developed 
in the 1960s. 
Recipient Operation 
The incidence of biliary duct complications (obstruction, 
fistula, and cholangitis), which had been more than 
30 %, was reduced by the use of choledochocholedo-
chostomy with aT-tube stent or, if this was not feasible, 
by choledochojejunostomy to a Roux limb. 1l9 The sys-
tematic use of venovenous bypasses without anticoagu-
lation in adult recipients greatly diminished the 
occurrence of hemorrhages of nightmare proportions 
that were common at one time. Management of coagu-
lopathies continued to be facilitated by the use of the 
thromboelastogram to follow the minute-to-minute clot-
ting changes in the operating room. 120 With better control 
of bleeding, scarring ,from mUltiple upper abdominal 
operations, as well as 'prior portosystemic shunts, were 
eliminated as serious adverse factors in major centers. 
The systematic use of arterial and venous grafts that 
was introduced in the 1970s24 eliminated extensive 
thrombosis of the portal and superior mesenteric veins 
as a contraindication to liver transplantationl21 and has 
facilitated arterialization in complex cases. 
The shortage of appropriate-sized donors for very 
small pediatric recipients was greatly ameliorated by 
the use of partial livers. The introduction of such oper-
ations followed the development of sophisticated tech-
niques of hepatic resection for neoplasms. 122,123 The 
first known reduced liver transplant graft operation 
was performed in Denver in 1975. 124 This case was not 
reported, however, until long after the description of 
the technique by Bismuth and Houssin in Paris35 and 
by Broelsch and Pichlmayr and colleagues in 
Hanover.36 Implantation of liver fragments has been 
facilitated by use of the piggyback principle,49 by which 
the recipient retrohepatic vena cava is kept intact and 
the venous outflow of the graft is anastomosed to cuffs 
of the host hepatic veins (Fig. 1-13). The piggyback mod-
ification was first used as early as 1968 in Cambridge, 
England69 and in Denver70 for the transplantation of pedi-
atric livers, but the operation was rarely used for full-
sized adult livers until its popularization by Tzakis and 
colleagues.J5 
Indications for Liver 
Transplantation 
By the early 1990s, liver transplantation had become 
the accepted court of last appeal for essentially all 
non-neoplastic end-stage liver diseases and for 
selected patients with otherwise nonresectable hepatic 
malignancies. 
Benign Disease 
Parenchymal and Cholestatic Disorder 
By the end of the 1980s, diagnoses that had precluded 
liver transplantation, such as the diagnosis of alcoholic 
cirrhosis, were no longer absolute contraindications. 
The list of benign diseases treatable by transplantation 
had become so long (nearly 100) that it was being divided 
into broad categories (Table 1-5) (e.g., cholestatic and 
parenchymal diseases) .125,126 
Inborn Errors of Metabolism 
Products of hepatic synthesis permanently retain 
the original metabolic specificity of the donor after 
Table 1-5. 
: TREATABLE BY LIVER 
Disease Category 
PARENCHYMAL 
Postnecrotic cirrhosis 
Alcoholic Cirrhosis 
Acute liver failure 
Budd-Chiari syndrome 
Congenital hepatic fibrosis 
Cystic fibrosis 
Neonatal hepatitis 
Hepatic trauma 
Others 
CHOLESTATIC 
Biliary atresia 
Primary biliary cirrhosis 
Sclerosing cholangitis 
Secondary biliary cirrhosis 
Familial cholestasis 
Others 
Inborn Errors of Metabolism 
TUMORS 
Benign 
Primary malignant 
Metastatic 
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• transplantation. Consequently, the correction of inborn 
errors by liver transplantation can be expected to 
endure for the life of the graft. By 1989, 16 liver-based 
or liver-influenced inborn errors of metabolism had 
been compiled (Table 1-6). Many others have been 
added since. 
NeoplastiC Diseases 
The early use of conventional liver transplantation to treat 
otherwise nonresectable primary or metastatic hepatic 
cancers resulted in a high rate of recurrence. 8.1l9,127 
Nevertheless, the use of liver transplantation to treat less-
advanced cancers has continued, almost invariably in 
combination with adjuvant chemotherapy or other proto-
cols. Certain kinds of neoplasms have a better prognosis 
than others. In an attempt to increase the perimeter of 
resectability, upper abdominal exenteration (i.e., en bloc 
removal of the liver, pancreas, spleen, stomach, duode-
num, proximal jejunum, and ascending colon) has been 
used to treat extensive sarcomas, carcinoid tumors, and 
other malignancies that are still regionally confined. 76 ,128 
The excised organs are replaced with hepatopancreatico-
duodenal grafts (see Fig, 1-6, top) or, in some cases, by 
the liver alone. 
Organ Shortage 
By the late 19805, there were enough liver transplant 
teams to use the available supply of deceased-donor 
organs. Efforts to equitably allocate livers to competing 
teams began officially in November 1987, when 
the United Network of Organ Sharing (UNOS) 
attempted to apply at a national level a point system 
based on urgency of need, size match, and logistic con-
siderations that had been in effect in western 
Pennsylvania for most of the 1980s.44 Neither the sys-
tem nor its many modifications has satisfied all of the 
caregivers, patient advocacy groups, and other stake-
holders. However, all interested groups, including sur-
geons, have tried to increase the pool of available 
organs. 
Use of Marginal Donors 
As early as 1986, Makowka and colleagues42 identified 
the impending organ shortage and reported the feasi-
bility of systematically using livers from older donors, 
donors with biochemical or histopathological evidence 
of liver injury, and those whose terminal course was 
characterized by management errors, physiological 
abnormalities, or the administration of potentially 
damaging pharmacological agents. At first criticized, 
this means of expanding the donor pool became widely 
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Table 1-6. INBORN ERRORS OF METABOLISM TREATED WITH LIVER TRANSPLANTATlON* 
Disease 
ai-Antitrypsin 
deficiency 
Wilson's disease 
Tyrosinemia 
Type I glycogen 
storage disease 
Type IV glycogen 
storage disease 
Cystic fibrosis 
Niemann-Pick disease 
Sea-blue histiocyte 
syndrome 
Erythropoietic 
proto porphyria 
Crigler-Najjer syndrome 
Type I hyperoxaluria 
Urea cycle enzyme 
deficiency ("three types) 
C protein deficiency 
Familial 
hypercholesterolemia 
Hemophilia A 
Hemophilia B 
Explanation of Disease 
Structural abnormality of the protease inhibitor 
synthesized in the liver 
Abnormal biliary copper excretion, decreased copper 
binding to ceruloplasmin, and copper accumulation 
in tissues; autosomal recessive gene mapped 
to chromosome 13 
Fumaroylacetoacetate hydrolase deficiency 
Glucose-6-phosphatase deficiency 
Amylo-1 :4,1 ;6-transglucosidase (branching 
enzyme) defect 
Unknown; pancellular disease, liver often affected 
Sphingomyelinase deficiency, sphingomyelin storage 
Unknown, neuroviscerallipochrome 
Hepatic ferrochelatase deficiency, ?overproduction of 
protoporphyrin by erythropoietic tissues 
Glucuronyl transferase deficiency 
Peroxisomal alanine: glyoxylate aminotransferase deficiency 
Ornithine carbamoyltransferase 
Defective C protein synthesis 
Low-density lipoprotein receptor deficiency, low-density 
lipoprotein overproduction 
Factor VIII deficiency 
Factor IX deficiency 
Survivel 
13 yr 
16.5 yr 
7.5 yr 
7 yr 
4,5 yr 
4.5 yr 
2 yr (died) 
7 yr 
1.5 yr 
4 yr 
8mo 
8mo 
2.5 yr 
6 yr 
4 yr 
6mo 
Disease 
Cirrhosis 
Cirrhosis 
Cirrhosis, hepatoma 
Glycogen storage, 
fibrosis, tumors 
Cirrhosis 
Cirrhosis 
None 
Cirrhosis 
Cirrhosis 
None 
None 
None 
None 
None 
Cirrhosis, a 
complication of 
blood component 
therapy 
Cirrhosis, a 
complication of 
blood component 
therapy 
*Most of the patients were in the University of Colorado-University of Pittsburgh series. This is a follow-up to January 1989. More 
inborn errors have been added since 1989. 
From Starzl TE, Demetris AJ, Van Thiel DH: Liver transplantation (1). N Engl J Med 321 :1014-1022, 1989. Reprinted by permission of 
The New England Journal of Medicine, 1989, Copyright 1989. Massachusetts Medical Society. 
accepted once the magnitude of the supply problem 
was appreciated. Serious and frequently contentious 
efforts are still being made to define what constitutes a 
marginal donor and how to decide who gets the liver. 129 
Living Donor Transplantation 
In an extension of the reduced liver graft procedures 
developed in deceased donors,35.36 portions of liver 
ranging from the leit lateral segment to the extended 
right lobe have been removed from volunteer adult 
donors for transplantation to pediatric recipients. 
Living donor liver transplantation from an adult liver to 
a child was first done successfully by Strong and Lynch 
in Adelaide, Australia.49 The operation for pediatric 
recipients was subsequently popularized by Christoph 
Broelsch and associates at the University of Chicago,SO 
who reported their results at the American Surgical 
Association conference in 1990 along with their experi-
ence with reduced-size deceased-donor organs and 
deceased-donor split livers. 
To obtain an adequate liver mass for recipient body 
weight in adult-to-adult living donor transplantation, 
the size of the transected liver fragment was first 
increased from the left lateral segment to a full left 
lobe. The more common operation today is transplan-
tation of a right lobe. This was first carried out in Japan 
? 
when unexpected anatomical findings were encoun-
tered in the donor. 54 The first cases and series of right 
lobe transplantation in the United States were not pub-
lished until 1998-1999.55 •56 Since then, more than 1500 
right lobe transplantations have been performed in 
more than 40 American centers with patient and graft 
survival equivalent to that with whole-organ, 
deceased-donor transplantation or with various kinds 
of partial liver transplantation, including the predeces-
sor adult-to-child procedure. 
Despite its utility, liver donation from a living donor 
has been used with caution by many liver transplant 
surgeons because it has had a mortality of approxi-
mately 0.5 %. 
Split-Liver Procedures 
More efficient use of deceased-donor organs has been 
made possible by sharing one liver between two recip-
ients. The split-liver procedure was first reported from 
Europe by Rudolf Pichlmayr in 1989 and soon there-
after by Bismuth (Paris) and Broelsch (Chicago). The 
results were inferior at first to those obtained with 
whole livers. 50 But after a learning curve and incorpo-
ration of the lessons learned from living donors, the 
results with livers split between adult and pediatric 
recipients have been comparable to standard deceased-
donor transplantation of whole organs. This practice may 
make the use of living donors for pediatric recipients 
unnecessary. 
Moreover, splitting of the adult liver into full left and 
right lobes for transplantation into two adults (or even 
the sharing of a pediatric liver by two infants or chil-
dren) could further relieve the organ shortage. This has 
been done successfully in a small number of adult 
cases. 130,131 Full implementation of this technique will 
require restriction of its use to optimal donors, careful 
assessment of the donor's physiological status before 
hepatectomy, careful consideration of the logistics 
involved, and the intelligent application of allocation 
rules for recipient selection.132 
Xenotransplantation 
Clinical transplantation of chimpanzee livers 12 was 
attempted three times between 1966 and 1973, with 
deaths after 0, 9, and 14 days,133 The clinical course 
and pathological findings in the two patients who sur-
vived the operation were indistinguishable from those 
after allotransplantation. Two additional hepatic xeno-
transplantations were attempted, in June 1992 and 
January 1993, with more phylogenetically distant 
baboon donors. Survival was 70 and 26 days.134.135 
Neither humoral nor cell-mediated rejection could be 
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indicted as the cause of failure in these cases. However, 
there was evidence of contfnuous complement activation 
in both. The xenografts did not function optimally, and 
both developed findings of intrahepatic cholestasis within 
the first postoperative week. It also was suspected that 
synthetic products of the baboon liver may have been 
incompatible with the human metabolic environment. 
The anthropomorphic qualities of chimpanzees and 
baboons and the perception that these animals pose a 
high risk from zoonotic infections have all but pre-
cluded further trials with primate donors. Hopes of 
using lower mammalian donors have been raised 
recently by the knockout in cloned pigs of both copies 
of the a1,3-galactosyltransferase gene. 58 The enzyme 
product of this gene is required for the synthesis of the 
sugar chain epitope a-gal, against which humans and 
other higher primates have preformed antibodies. 
Elimination (double knockout) of the a-gal epitope 
avoids the immediate innate immune response to pig 
organs (i.e., hyperacute rejection does not occur), but 
it is almost certain that other genetic modifications will 
be needed before pig organs will be suitable for clinical 
use. Even if the immune barrier to livers is controlled, 
the multiple synthetic products of the porcine liver 
could make pig-to-human liver xenotransplantation tan-
tamount to endowment of an inborn error (or errors) of 
metabolism. 
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